SEARAINBOW(SZ:000503) Jing Ji Guan Cha Wang·2026-02-13 10:23Core Viewpoint - Guoxin Health (000503) anticipates a net profit loss of 409 million yuan for 2025, primarily due to fair value changes in investment assets, while focusing on core business development in data elements and AI healthcare [1][2]. Financial Performance - For 2025, Guoxin Health expects total revenue of 351 million yuan, remaining stable compared to the previous year; the net profit attributable to shareholders is projected to be -409 million yuan, mainly due to a loss of approximately 260 million yuan from the fair value changes of trading financial assets (Shenzhou Medical Technology) [2]. - The net profit after excluding non-recurring gains and losses is expected to be -148 million yuan, indicating stable performance in core business [2]. Company Status - On February 6, 2026, the company held its 12th board meeting to review a proposal regarding the management of temporarily idle raised funds, with further announcements expected regarding the implementation of this proposal [3]. Industry Policy and Environment - The medical information industry faced overall pressure in 2025, with over half of the companies in the sector forecasting negative net profits excluding non-recurring items. Guoxin Health emphasized its commitment to advancing health big data applications in medical insurance management and quality, aligning with the "Healthy China" and "Three Medical Collaborations" strategies [4]. Stock Performance - As of February 9, 2026, Guoxin Health's stock price is 9.46 yuan per share, with a total market capitalization of 9.264 billion yuan. The stock has increased by 6.53% year-to-date but has decreased by 18.52% over the past 20 days. The net outflow of main funds on that day was 291,700 yuan [5].